CIHR > Funding Health Research > Funding Opportunities > Archived Funding Opportunities

Operating Grants - Genomic Medicine and Human Development (Archived)

Note: The content of this RFA has been updated.
See table of contents for the applicable section.

Request for Applications

Institute of Genetics

In partnership with

The Foundation Fighting Blindness - Canada
Heart and Stroke Foundation of Canada
Institute of Aboriginal Peoples' Health
Institute of Circulatory and Respiratory Health
Institute of Gender and Health
Institute of Human Development, Child and Youth Health
Institute of Musculoskeletal Health and Arthritis

Summary

Important advances have been made with respect to our understanding of the genetic factors governing normal and abnormal developmental processes, but the impact on medical practice to date has been limited. The purpose of this Request for Applications (RFA) is to provide operating grants in support of projects that bridge clinical investigation and more basic scientific research to address an important problem in human development. Applications are invited from individual investigators and from teams of investigators.

Timeline

April 1, 2005	Letter of Intent Deadline - Letter of Intent must be courier stamped by this date.
May 15, 2005	Letter of Intent decision.
August 15, 2005	Full Application Deadline - Full applications must be courier stamped by this date.
November 2005	Anticipated Notification of decision.
November 2005	Anticipated start date.

Value and Duration

Duration of projects	Up to five years.
Funds Available	For this initiative: $10.25 million, for a total of five years, at a minimum. Per grant: Up to $500,000 per year. Larger amounts will be considered in extraordinary circumstances, if justified. At the LOI stage, applicants may request funds of up to $10,000 to be used in the development of the full application.

Investigators interested in this RFA may wish to visit the related funding opportunity, from the Institute of Neurosciences, Mental Health and Addiction:
Early Life Events and First Episodes of Brain Disorders

Summary
Background
Partners
Objectives
Eligible Research Areas and Requirements
Funding Information
Eligibility
Evaluation Criteria and Process (Updated: 2005-02-09)
General CIHR Guidelines and Conditions of Funding
Communications Requirements
Monitoring, Performance Measurement and Evaluation
How to Apply
Contact Information
Description of Partners

Background

"From Genes to Genomic Medicine" is a strategic research priority theme of the CIHR Institute of Genetics (IG). This theme emerged from various workshops and consultations with the community, led and sponsored by the IG. One of the key goals of the "From Genes to Genomic Medicine" Initiative is to address the increasing need to translate scientific advances in our understanding of basic developmental processes, genetics and genomics into medical practice. The approach taken for this Request for Applications (RFA) is to build on existing Canadian strengths in developmental genetics and clinical research.

The purpose of this RFA is to provide operating grants in support of research projects designed to foster research that bridges clinical investigation and more basic scientific research to address an important problem in human development.

Partners

The Institute of Genetics is dedicated to identifying and developing collaborations with other CIHR institute(s), branch(es) or office(s), funding organizations and stakeholders to enhance the availability of funding for this strategic initiative, and to create, where appropriate, opportunities for knowledge exchange and translation related to the scope of this particular initiative. Applicants are invited to visit the Description of Partners to find a list of partners and their respective mandates and/or strategic interests. This list will continue to evolve as new partners join in this initiative. The specific research foci and requirements for each partner are outlined in the section "Objectives and Eligible Research Areas."

Objectives

The objectives of this initiative are:

To facilitate research that bridges clinical and more basic scientific expertise, so as to strengthen the study of an important problem in human development;
To produce demonstrable international impact of Canadian research on human development; and
To foster the translation of research findings into clinical applications.

Eligible Research Areas and Requirements

In alignment with the specific objectives of this initiative, applications must address ALL of the following requirements:

addresses an important problem in human development (i.e., cellular differentiation or determination, embryogenesis, fetal development, and the subsequent structural and functional maturation of the child)
includes work on human subjects, families or populations, clinical data or samples obtained from human subjects;
involves both clinical research expertise and basic scientific expertise;
enhances pathogenic understanding, diagnosis or management of a human clinical condition that is currently poorly understood;
promotes the application of fundamental knowledge in developmental biology or developmental genetics to clinical medicine, enhances the fundamental understanding of human development gained through clinical research, or both;
builds on existing Canadian strengths in developmental biology, clinical research or both; and
shows clear potential for clinical application within 5-10 years.

The Foundation Fighting Blindness - Canada invites research proposals that will advance the understanding of the causes and improve the diagnosis, prevention, and treatment of retinal developmental disorders that affect vision. The Foundation gives high priority to studies of clear and direct relevance to developmental disorders of the retina, including genetics, molecular genetics, molecular biology, biochemistry and cell biology studies of human subjects, animal or cellular models. Recognizing, however, that the properties of the retina cells and tissues most affected by these developmental disorders are often shared by other cells and tissues, the Foundation also invites more general studies of high merit on general developmental processes that have broad relevance to developmental aspects of the retina.

The Heart and Stroke Foundation of Canada will fund proposal(s) in research area(s) related to congenital heart defects. Congenital heart defects are one of the most prevalent and serious congenital defects affecting children. There are a number of types of congenital heart defects such as, stenoses, holes in the heart, patent ductus arteriosus, cyanotic heart defects and Ebstein's anomaly, which occur in approximately 10-12 cases per 1000 live births in Canada. Understanding why and how congenital heart defects occur and the underlying genetic mechanisms and protein expression, may provide insight in to how to test for certain defects and the development of new diagnostic tools. Please note that proposals related to congenital heart defects must also address the requirements listed (i) through (vii) as outlined in the Eligible Research Areas and Requirements section.

The Institute of Aboriginal Peoples' Health (IAPH) supports research to address the special health needs of Canada's Aboriginal people. Depending on available resources, through this RFA the CIHR-IAPH will support research that contributes to the improvement of the health and well-being of First Nations, Inuit and/or Métis people. It will support innovative research projects that generate new knowledge based on scientific excellence, cultural relevance and community collaboration. Applicants should also build partnerships and alliances between aboriginal communities and relevant health research organizations/institutes at the local, regional and/or national levels.

The Institute of Circulatory and Respiratory Health (ICRH) will provide funding toward grant(s) which are responsive to the requirements listed above and are of relevance to the ICRH's mandate.

The Institute of Gender and Health (IGH) will support research to address how sex (biological factors) and gender (socio-cultural experiences) interact with other factors that influence health to create conditions and problems that are unique, more prevalent, more serious or different with respect to risk factors or effective interventions for women and men throughout the lifespan.
Five research priorities were identified in 2001 through extensive national consultations. This RFA is relevant to the following IGH research priorities: Promoting health in context of chronic conditions and disabilities, Gender and health across the lifespan, and Gender and the environment.

Examples of eligible research areas that are relevant to IGH include but are not limited to studies of:

Maternal and paternal inheritance patterns
Interactions of hormones with genetic factors and the impact of these interactions on the health of females and males in specific organ systems
Hormone-mediated influences on male and female development at different life stages (e.g., fetal development, puberty, pregnancy, menopause, etc).

The IGH strongly encourages applicants to demonstrate the use of gender-based or gender-sensitive analysis (GBA) in applications. GBA is an approach to research and evaluation which systematically inquires about biological (sex-based) and sociocultural (gender-based) differences between women and men, boys and girls, without presuming that any such differences exist. The purpose of GBA is to promote rigorous sex/gender-sensitive health research which expands understanding of health determination in both sexes, in order to provide knowledge which can result in improvements in health and health care. IGH is currently examining various ways to stimulate substantive GBA practice among the research community. In the meantime, we refer you to the Canadian resource on GBA policy and practice published by Health Canada which can be found at the web addresses below. Applications with explicit reference to how they incorporate sex or gender considerations in the development of the research question, methodology and analysis will receive favourable pre- and post- peer review funding consideration from IGH.

Health Canada - Women's Health - Gender-based Analysis
Health Canada - Women's Health - What is Gender-Based Analysis?

Please note that if you locate and/or use alternate sex and gender sensitive guidelines, we would appreciate their citation.

The Institute of Musculoskeletal Health and Arthritis encourages researchers across disciplines within the Arthritis, Bone, Skin, Muscle, Oral Health and/or Rehabilitation Research communities, and across all four of CIHR research pillars to develop research in areas covered by IMHA's three research themes:

Examples of research that might be conducted under this Request for Applications are provided below. (These examples are not intended to be exhaustive, and there is no intent to imply that applications in these particular research areas would be more successful than applications in other research areas. The applications approved will be those judged by peer review to be the strongest ones that meet the criteria specified above and may include none of the examples given below).

Elucidation of developmental mechanisms involved in multifactorial congenital heart defects;
Studies of the embryonic consequences of mutations that cause cancer;
Validation of genetic, biochemical, imaging or functional analysis tools for clinical diagnosis or management of individuals with a developmental disorder;
Characterization in a model system of novel genes identified in mentally handicapped children with chromosomal microdeletions;
Characterization of genes that produce susceptibility to teratogenic effects;
Utilization and/or creation of model systems to identify and test novel therapies for developmental diseases;
Development and clinical validation of novel, mechanism-based therapies for a developmental disorder; or
Studies of the genetic mechanisms producing variable adaptive responses to medications used either during development or for the treatment of developmental disorders;
Finding new cancer therapies by comparing normal stem cell pathways and human cancers.

Funding Information

Mechanism of Support

This RFA is funded as a strategic initiative and is designed to solicit operating grant applications with the duration of up to five years.

This Request for Applications will follow the General Guidelines for All Research Funding Grants.

Allowable Costs

Applicants should review Use of Grant Funds and Eligibility of Expenses, Employment under Grants within the General Guidelines for All Research Grants for a complete listing and description of allowable costs and activities.

The full application must provide a detailed justification of all costs.

Funds Available

The maximum amount awarded for a single grant is $ 500,000 per annum for up to five years, including equipment, which is awarded in year one. Larger amounts will be considered in extraordinary circumstances, if justified.
The total amount available for this initiative is $ 10 million, at a minimum. This amount may increase if additional funding partners decide to participate.

Based on the total funds available for the initiative, applications will be funded from the top-ranked down as far as budgets will allow. Applications receiving a score between 3.5 - 3.7 are unlikely to be considered for funding. Applications receiving a score of less than 3.5 will not be considered for funding.

Eligibility

Eligibility Criteria

Eligibility criteria for all CIHR research funding programs apply. The business office of the institution of an eligible Nominated Principal Applicant generally administers CIHR funds. Please refer to the Eligibility Requirements for CIHR Grants and Awards regarding the eligibility requirements for individuals and institutions.

Evaluation Criteria and Process

Evaluation Criteria

General criteria for assessing applications are listed below. Because different applications will emphasize different approaches to research and to knowledge translation, it is understood that reviewers and committees will weigh questions such as these differently from one application to another.

The research proposed:

How important, novel and/or original are the hypotheses or the questions to be addressed, and how clearly are they formulated?
How important and original are the contributions expected from the research proposed? What is the potential for important new knowledge or impact in health research?
How well will the proposed experiments address the hypotheses or questions? How appropriate are the methods for the conduct of the experiment and analysis of data? How well have the applicants anticipated difficulties in their approach and considered alternatives?
How critically is the relevant literature appraised and evaluated?

The applicant's productivity, experience and training:

How appropriate to the research proposed is the training or track record of the applicant(s)? How important and original is the recent productivity of the applicant(s)? How much confidence do you have that the applicant can do the work proposed? (The proposed time commitment to the research may influence this judgment).

Additional criteria

In addition to these general criteria, the peer review committee will consider if applications meet ALL of the requirements under "Eligible Research Areas and Requirements":

addresses an important problem in human development (i.e., cellular differentiation or determination, embryogenesis, fetal development, and the subsequent structural and functional maturation of the child);
includes work on human subjects, families or populations, clinical data or samples obtained from human subjects;
involves both clinical research expertise and basic scientific expertise;
enhances pathogenic understanding, diagnosis or management of a human clinical condition that is currently poorly understood; within 5-10 years.
promotes the application of fundamental knowledge in developmental biology or developmental genetics to clinical medicine, enhances the fundamental understanding of human development gained through clinical research, or both;
builds on existing Canadian strengths in developmental biology, clinical research or both; and
shows clear potential for clinical application within 5-10 years.

Evaluation Process

All personal information collected by CIHR about applicants is used to review applications, to administer and monitor grants and awards, to compile statistics, and to promote and support health research in Canada. Consistent with these purposes, applicants should also expect that information collected by CIHR may be shared as described in Use and Disclosure of Personal Information Provided to CIHR for Peer Review.

Development grants may be awarded upon the recommendation of the Letter of Intent review committee.

Letters of Intent (LOI) will be reviewed by the LOI review panel, composed of expert reviewers. LOIs will be reviewed for relevance to partner strategic interests and the objectives and eligible research areas, as outlined in the RFA. Panel members will have access to the anonymized project titles and summaries for this purpose. CIHR Institutes and partner representatives will also have access to the anonymized LOIs.

In the event that many more LOIs pass the relevance review than can be supported with the funds available for this competition, CIHR will introduce a scientific merit review of the relevant LOIs. This scientific merit review will be based on the full information available in the LOI, and will be conducted according to CIHR's normal practice. This additional merit review is intended to prevent applicants who are unlikely to be competitive, due to limitations in available funding, from expending the time and effort involved in writing a full application. Applicants whose LOI is approved as relevant, or both relevant and scientifically meritorious, will be invited to submit a full application.

A CIHR peer review committee will evaluate the full applications. The committee may be drawn from one of CIHR's pre-existing committees or may be created specifically for this Request for Applications. Committee members are selected based on suggestions from many sources including the institute(s) / portfolio(s) and partner(s), following CIHR's policy on Conflict of Interest, Confidentiality and Privacy Issues in Peer Review. For information on CIHR's peer review process, see Peer Review.

On completion of the peer review, the appropriate CIHR institute, portfolio and partner representatives will receive the ranking list, merit scores (ratings) and recommendations of the peer review committee with regards to funding level, for the submitted applications that fall in the fundable range.

Access to Information Act and Privacy Act, and the Personal Information Protection and Electronic Documents Act (PIPEDA)

CIHR as a federal entity is subject to the Access to Information Act and the Privacy Act, therefore the requirements of these two statutes will apply to all information located in CIHR's premises including, without limitation, cost-sharing agreements related to this Request for Applications and all matters pertaining thereto.

The Parties, while respecting the application of the Privacy Act to federal entities, will also be bound by the PIPEDA. All personal information (as identified by the PIPEDA) collected, used or disclosed in the course of any commercial activity under cost-sharing agreements related to the Request for Applications will be collected, used and disclosed in compliance with the PIPEDA.

General CIHR Guidelines and Conditions of Funding

All conditions specified in CIHR General Grants and Awards Policies shall apply to applications funded through this Request for Applications. Conditions cover areas such as Applicant and Institutional Responsibilities, Ethics, Official Language Policy, Access to Information and Privacy Acts, and Acknowledgement of CIHR Support. Successful applicants will be informed of any special financial conditions prior to the release of funds or when they receive CIHR's Authorization for Funding (AFF) document.

In addition to CIHR standard guidelines and requirements, the following special conditions shall apply:

Within six months after the end of the grant's term, the Nominated Principal Applicant is required to submit a final performance report, summarizing the results and describing how the grant funds were used. A standard form will be provided by CIHR.

Communications Requirements

Grant recipients are required to acknowledge HSFC, and CIHR institutes: ICRH, IG and IHDCYH in any communication or publication related to the project. See CIHR General Grants and Awards Policies, Acknowledgement of CIHR's Support for details on CIHR's communication requirements. The contributing institutes / partners will be identified on the Authorization for Funding and decision letter.

Monitoring, Performance Measurement and Evaluation

CIHR is committed to demonstrating results to Canadians for the money invested in health research. Therefore, processes for monitoring progress and appropriate use of funds, as well as for performance measurement and program evaluation are in place. As a result, funding recipients must:

adhere to CIHR's reporting requirements and provide required information in a timely fashion. A progress report will be required in year 3 of five-year grants. Grantees are required to submit a "Progress Report for 5-year grant holder (Form 44)" which can be found under All Forms and Guidelines for Completion describing the progress made and the publications issued since the start of the grant. CIHR will cancel the last 12 months of the grant if the progress is unacceptable and will cancel the final two years of the grant if it does not receive a report;
contribute to the monitoring, review and evaluation of CIHR's programs, policies and processes by participating in evaluation studies, surveys, workshops, audits and providing data or reports as required for the purpose of collecting information to assess progress and results;
encourage their associates, trainees and administration to participate in the monitoring, review and evaluation of CIHR's programs, policies and processes as required.

The following table is intended to further clarify objectives by linking them to expected outcomes and measures which will be included in CIHR's Management Resources and Results Structure (MRRS) required by Treasury Board.

Objective	Outcome	Measure / Indicator
Facilitate research that bridges clinical and more basic scientific expertise, so as to strengthen the study of an important problem in human development	Increased research activity in this area	Number and value of grants awarded
	Increased research activity in this area	Increases in research funding from CIHR open competition and other sources
	Increased interdisciplinary, inter-pillar collaborations	Number, composition and quality of research collaborations and teams
Produce demonstrable international impact of Canadian research on human development	Demonstrable impact on the international scene	Increase in number and quality of peer-reviewed reports in this research field
Foster the translation of research findings into clinical applications	Development of clinical applications	Change in pattern of clinical practice in the next 5-10 years

How to Apply

The application process is comprised of two steps: 1) Letter of Intent (LOI), and 2) Full Application.

1. Letter of Intent (LOI)

In the first step of the application process the Nominated Principal Applicant is required to submit a Letter of Intent.

The Letter of Intent should include:

a) A cover page (maximum one page) indicating:

the title of the program as it will appear in publicity and other announcements;
the relevant area of focus;
the name, title, address, telephone and fax numbers, and E-mail address of the Principal Applicant; and,
a statement indicating which university or affiliated institution will administer the funds.

b) A list of all team members and their affiliations. (N.B., The list need not be final at the Letter of Intent stage).

c) The CIHR Research Module - "Research Funding Programs" section (Cover page of the Web Form printed report)

d) The CIHR Research Module - "Applicants/Co-Applicants" section (Page 2a "Signature page" of the Web Form printed report).

e) Letter.

In a maximum of three pages, the letter should outline clearly each of the elements below:

Research program and relevancy. Describe the program and justify why it is responsive to this Request for Applications - as outlined in the Objectives and Eligible Research Area and requirements sections - including a brief description of the:
1. Objectives of the research program; and
2. Individual research components that make up the program.
Team (if applicable). Describe the team including the nature and extent of the collaboration between investigators, with an explanation of the anticipated added value added to the research program through the formation of the team. Justify the capacity of the individual(s) identified as Principal Applicant(s) to lead a group project.
Research Plan and Schedule. Outline the preliminary plan for the research program and schedule of work; and,
Other Funding. It is expected that the researcher or team members may be receiving funding for their work from their host institution/department or other sources for this proposed project. This funding will be included in assessments of the monetary value of any given project and is therefore advantageous.

f) Attachments:

A brief curriculum vitae (CV) (maximum two pages) for each Principal Applicant. The curriculum vitae must include information on current grants requested held, relevant publications from the last five years, and expertise keywords. Full CVs will not be considered;
A development grant request (if needed), whereby applicants may request funds of up to $10,000 to be used in the development of a full application. A one-page request must be submitted with the LOI, outlining the development grant budget;
A short bibliography (one page) of any references cited in the Letter of Intent;
A list of the areas of expertise of the team members.

Applicants are advised to follow the Mandatory Instructions for Data Entry which outline formatting requirements for attachments.

Any additional material will be discarded and not sent to the review committee; this includes letters of support, updates on publications, updates on other support received, letters confirming academic appointment, reprints, etc.

Send the Letter of Intent by Courier to:

Submit one original and six copies of the Letter of Intent to the address below, by April 1, 2005.

RE: "Genomic Medicine and Human Development"
Canadian Institutes of Health Research
Room 97, 160 Elgin Street
Address locator: 4809A
Ottawa, Ontario K1A 0W9

2. Full Application

Selected applicants will be invited to submit a full application by August 15, 2005.

Full application:

Complete the full application using the CIHR Operating Grants application package which consists of the CIHR Research Module, the CIHR Operating Budget Module and a Common CV for each applicant and co-applicant participating in the research project.
For team applications only, when completing CIHR Research Module, provide full description of the individual components making up the team's research program, as well as the justification for supporting the collaborative aspects of the entire proposal.
When completing the CIHR Operating Budget Module provide a detailed justification of all project costs.

Send the Full Application by Courier to:

Submit one original and eight copies of the Full Application to the address below, by August 15, 2005.

RE: "Genomic Medicine and Human Development"
Canadian Institutes of Health Research
Room 97, 160 Elgin Street
Address locator: 4809A
Ottawa, Ontario K1A 0W9

Contact Information

For questions on CIHR funding guidelines, how to apply, and the peer review process contact:

Tina Lawton
Acting Program Delivery Officer
Canadian Institutes of Health Research
Telephone: (613) 941-1068
Fax: (613) 954-1800
E-mail: tlawton@cihr-irsc.gc.ca

For questions about this initiative and research objectives contact:

Milka Popov, PhD
Assistant Director
CIHR Institute of Genetics
123 Edward Street, Suite 1211
Toronto, ON M5G 1E2
Tel: (416) 813-7670
Fax: (416) 813-7673
E-mail: milkaig@sickkids.on.ca

Anne-Cécile Desfaits, PhD
Assistant Director
CIHR - Institute of Human Development, Child and Youth Health (IHDCYH)
Telephone: (514) 412-4414
Fax: (514) 412-4253
E-mail: sfaits@irsc-cihr.gc.ca

Lynne Moffatt
Assistant Director, Strategic Research Initiatives
Heart and Stroke Foundation of Canada
222 Queen Street #1402
Ottawa, ON K1P 5V9
Tel: (613) 569-4361, ext. 350
E-mail: LMoffatt@hsf.ca

Elizabeth Hurdman
Manager, Research & Information Programs
The Foundation Fighting Blindness - Canada
Telephone: 416-360-4200
Fax: 416-360-0060
E-mail: ehurdman@ffb.ca

Sophia Tsouros
Project Manager / Analyst
CIHR - Institute of Musculoskeletal Health and Arthritis
Telephone: (613) 954-3469
Fax: (613) 954-1800
E-mail: stsouros@cihr-irsc.gc.ca

Ilana Kogan Gombos, PhD
Assistant Director
CIHR - Institute of Gender and Health
700 University Extension Centre
8303 - 112th Street
Edmonton, Alberta
T6G 2T4
Tel: (780) 492-3656
Fax: (780) 492-3689
E-mail: ikg@ualberta.ca

Description of Partners: CIHR Institutes and Partner Organizations

Canadian Institutes of Health Research (CIHR)
CIHR is Canada's major federal funding agency for health research. Its objective is to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health care system.

Partners:

Additional partners, including partners from industry and the private sector, are expected to join this funding initiative over the coming year.

The Foundation Fighting Blindness - Canada (FFBC)
The mission of The Foundation Fighting Blindness is to find the causes, treatments and ultimately the cures for retinitis pigmentosa, macular degeneration and related retinal diseases by the support and promotion of research and the development of public awareness.

Heart and Stroke Foundation of Canada (HSFC)
The mission of the HSFC is to improve the health of Canadians by preventing and reducing disability and death from heart disease and stroke through research, health promotion and advocacy. The Foundation is a leading funder of heart disease and stroke research in Canada and is committed to supporting research across the full research spectrum.

CIHR - Institute of Aboriginal Peoples' Health (IAPH)
CIHR-IAPH supports research to address the special health needs of Canada's Aboriginal people. Depending on available resources, through this RFA the CIHR-IAPH will support research that contributes to the improvement of the health and well-being of First Nations, Inuit and/or Métis people. It will support innovative research projects that generate new knowledge based on scientific excellence, cultural relevance and community collaboration. Applicants should also build partnerships and alliances between aboriginal communities and relevant health research organizations/institutes at the local, regional and/or national levels.

CIHR - Institute of Circulatory and Respiratory Health (ICRH)
ICRH supports research into causes, mechanisms, prevention, screening, diagnosis, treatment, support systems, and palliation for a wide range of conditions associated with the heart, lung, brain (stroke), blood, blood vessels, [critical care] and [sleep].

CIHR - Institute of Genetics (IG)
IG mandate is to support research on the human and other genomes and on all aspects of genetics, basic biochemistry and cell biology related to health and disease, including the translation of knowledge into health policy and practice, and the societal implications of genetic discoveries.

CIHR - Institute of Human Development, Child and Youth Health (IHDCYH)
IHDCYH supports research to enhance maternal, child, and youth health and to address causes, prevention, screening, diagnosis, treatment, short- and long-term support systems, and palliation for a wide range of health concerns associated with reproduction, early development, childhood, and adolescence.

The specific research foci and requirements for each partner are outlined in the section "Eligible Research Areas and Requirements."

IG is dedicated to identifying and developing collaborations with other CIHR institute(s), branch(es) or office(s), funding organizations and stakeholders to enhance the availability of funding for this strategic initiative, and to create, where appropriate, opportunities for knowledge exchange and translation related to the scope of this particular initiative.

CIHR - Institute of Gender and Health (IGH)
The mandate of the CIHR Institute of Gender and Health (IGH) supports research that addresses how sex (biological-genetic factors) and gender (social-cultural experiences) interact with other socio-cultural, bio-physical, and political-economic factors to influence health, and create conditions that differ with respect to risk factors or effective interventions for males and females throughout the lifespan.

CIHR - Institute of Musculoskeletal Health and Arthritis
The goal of the CIHR - Institute of Musculoskeletal Health and Arthritis is to support research to sustain health and enhance quality of life by eradicating the pain, suffering and disability caused by arthritis, musculoskeletal, oral and skin conditions.

Created: 2004-12-15
Modified: 2005-09-30
Reviewed: 2005-01-05
Print

Top of Page

Important Notices

Français	Contact Us	Help	Search	Canada Site
CIHR Home	About CIHR	What's New	Funding Opportunities	Funding Decisions